Targeting cardiovascular risk in rheumatoid arthritis: A dual role for statins

Nature Reviews Rheumatology

Volumn 6, Issue 3, 2010, Pages 157-164

  Bisoendial, Radjesh J ^a   Stroes, Erik S G ^a   Kastelein, John J P ^a   Tak, Paul Peter ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRHEUMATIC AGENT; ATORVASTATIN; CHLOROQUINE; CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; EZETIMIBE; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METHOTREXATE; PLACEBO; RHEUMATOID FACTOR; SIMVASTATIN; TUMOR NECROSIS FACTOR INHIBITOR;

ABSENCE OF SIDE EFFECTS; ADAPTIVE IMMUNITY; ADD ON THERAPY; ANTIINFLAMMATORY ACTIVITY; ARTHRITIS; ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DISEASE ACTIVITY; DRUG INDICATION; DRUG MEGADOSE; ENDOTHELIUM CELL; HEART PROTECTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPOPROTEINEMIA; IMMUNOMODULATION; IN VITRO STUDY; INFLAMMATION; INNATE IMMUNITY; LIPOPROTEIN BLOOD LEVEL; LOW DRUG DOSE; MORTALITY; NONHUMAN; PATHOPHYSIOLOGY; PREDICTION; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR; RISK MANAGEMENT; RISK REDUCTION; STEM CELL;

ANTI-INFLAMMATORY AGENTS; ANTICHOLESTEREMIC AGENTS; ARTHRITIS, RHEUMATOID; CARDIOVASCULAR DISEASES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; RISK FACTORS;

EID: 77949265960     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2009.277     Document Type: Review

References (89)

1. Wolfe, F. et al. The mortality of rheumatoid arthritis. Arthritis Rheum. 37, 481-494 (1994).
2. Solomon, D. H. et al. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 107, 1303-1307 (2003).
3. Krishnan, E., Lingala, V. B. & singh, G. Declines in mortality from acute myocardial infarction in successive incidence and birth cohorts of patients with rheumatoid arthritis. Circulation 110, 1774-1779 (2004).
4. Choi, H. K., Hernan, M. A., Seeger, J. D., Robins, J. M. & Wolfe, F. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 359, 1173-1177 (2002).
5. Kremer, J. M. Safety, efficacy, and mortality in a long-term cohort of patients with rheumatoid arthritis taking methotrexate: followup after a mean of 13.3 years. Arthritis Rheum. 40, 984-985 (1997).
6. Thavendiranathan, P., Bagai, A., Brookhart, M. A. & Choudhry, N. K. Primary prevention of cardiovascular diseases with statin therapy: a meta-analysis of randomized controlled trials. Arch. Intern. Med. 166, 2307-2313 (2006).
7. Ridker, P. M. et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N. Engl. J. Med. 359, 2195-2207 (2008).
8. Versmissen, J. et al. efficacy of statins in familial hypercholesterolaemia: a long term cohort study. BMJ 337, a2423 (2008).
9. Penning-van Beest, F. J. et al. Adherence to evidence-based statin guidelines reduces the risk of hospitalizations for acute myocardial infarction by 40%: a cohort study. Eur. Heart J. 28, 154-159 (2007).
10. Brugts, J. J. et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. BMJ 338, b2376 (2009).
11. Collins, R., Armitage, J., Parish, S., sleight, P. & Peto, R. effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet 363, 757-767 (2004).
12. Bisoendial, R. J. et al. Measurement of subclinical atherosclerosis: beyond risk factor assessment. Curr. Opin. Lipidol. 13, 595-603 (2002).
13. Bergholm, R. et al. Impaired responsiveness to NO in newly diagnosed patients with rheumatoid arthritis. Arterioscler. Thromb. Vasc. Biol. 22, 1637-1641 (2002).
14. Bosello, S. et al. TNF-alpha blockade induces a reversible but transient effect on endothelial dysfunction in patients with long-standing severe rheumatoid arthritis. Clin. Rheumatol. 27, 833-839 (2007).
15. Hurlimann, D. et al. Anti-tumor necrosis factoralpha treatment improves endothelial function in patients with rheumatoid arthritis. Circulation 106, 2184-2187 (2002).
16. Gonzalez-Juanatey, C. et al. short-term improvement of endothelial function in rituximabtreated rheumatoid arthritis patients refractory to tumor necrosis factor alpha blocker therapy. Arthritis Rheum. 59, 1821-1824 (2008).
17. Gonzalez-Juanatey, C. et al. Increased prevalence of severe subclinical atherosclerotic findings in long-term treated rheumatoid arthritis patients without clinically evident atherosclerotic disease. Medicine (Baltimore) 82, 407-413 (2003).
18. Gerli, R. et al. early atherosclerosis in rheumatoid arthritis: effects of smoking on thickness of the carotid artery intima media. Ann. NY Acad. Sci. 1051, 281-290 (2005).
19. Chung, C. P. et al. Increased coronary-artery atherosclerosis in rheumatoid arthritis: relationship to disease duration and cardiovascular risk factors. Arthritis Rheum. 52, 3045-3053 (2005).
20. Kao, A. H. et al. subclinical coronary artery calcification and relationship to disease duration in women with rheumatoid arthritis. J. Rheumatol. 35, 61-69 (2008).
21. Roman, M. J. et al. Preclinical carotid atherosclerosis in patients with rheumatoid arthritis. Ann. Intern. Med. 144, 249-256 (2006).
22. Yalamanchili, K. et al. Coronary artery disease is more severe in older persons with rheumatoid arthritis than in older persons without rheumatoid arthritis. Cardiol. Rev. 14, 55-56 (2006).
23. Warrington, K. J. et al. Rheumatoid arthritis is an independent risk factor for multi-vessel coronary artery disease: a case control study. Arthritis Res. Ther. 7, R984-R991 (2005).
24. Gordon, S. The macrophage: past, present and future. Eur. J. Immunol. 37 (suppl. 1), s9-s17 (2007).
25. Martinez, F. O., Sica, A., Mantovani, A. & Locati, M. Macrophage activation and polarization. Front. Biosci. 13, 453-461 (2008).
26. Hamilton, J. A. & Tak, P. P. The dynamics of macrophage lineage populations in inflammatory and autoimmune diseases. Arthritis Rheum. 60, 1210-1221 (2009).
27. Tracey, D., Klareskog, L., Sasso, E. H., Salfeld, J. G. & Tak, P. P. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol. Ther. 117, 244-279 (2008).
28. Speiser, W. et al. effect of intradermal tumor necrosis factor-alpha-induced inflammation on coagulation factors in dermal vessel endothelium. An in vivo study of human skin biopsies. Thromb. Haemost. 85, 362-367 (2001).
29. Patel, J. N. et al. effects of tumour necrosis factor-alpha in the human forearm: blood flow and endothelin-1 release. Clin. Sci. (Lond.) 103, 409-415 (2002).
30. Liang, J. et al. Macrophage metalloelastase accelerates the progression of atherosclerosis in transgenic rabbits. Circulation 113, 1993-2001 (2006).
31. Yvan-Charvet, L. et al. Increased inflammatory gene expression in ABC transporter-deficient macrophages: free cholesterol accumulation, increased signaling via toll-like receptors, and neutrophil infiltration of atherosclerotic lesions. Circulation 118, 1837-1847 (2008).
32. Zernecke, A. et al. Protective role of CXC receptor 4/CXC ligand 12 unveils the importance of neutrophils in atherosclerosis. Circ. Res. 102, 209-217 (2008).
33. Bisoendial, R. J. et al. effects of CRP infusion on endothelial function and coagulation in normocholesterolemic and hypercholesterolemic subjects. J. Lipid Res. 48, 952-960 (2007).
34. Wu, G. et al. Complement regulator CD59 protects against atherosclerosis by restricting the formation of complement membrane attack complex. Circ. Res. 104, 550-558 (2009).
35. Andresdottir, M. B., Sigfusson, N., Sigvaldason, H. & Gudnason, V. Erythrocyte sedimentation rate, an independent predictor of coronary heart disease in men and women: the Reykjavik study. Am. J. Epidemiol. 158, 844-851 (2003).
36. Ridker, P. M., Hennekens, C. H., Buring, J. E. & Rifai, N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N. Engl. J. Med. 342, 836-843 (2000).
37. - T lymphocytes contribute to early atherosclerotic damage in rheumatoid arthritis patients. Circulation 109, 2744-2748 (2004).
38. Namekawa, T., Wagner, U. G., Goronzy, J. J. & Weyand, C. M. Functional subsets of CD4 T cells in rheumatoid synovitis. Arthritis Rheum. 41, 2108-2116 (1998).
39. - T cells in rheumatoid arthritis patients combine features of the innate and adaptive immune systems. Arthritis Rheum. 44, 13-20 (2001).
40. Eid, R. E. et al. Interleukin-17 and interferongamma are produced concomitantly by human coronary artery-infiltrating T cells and act synergistically on vascular smooth muscle cells. Circulation 119, 1424-1432 (2009).
41. Galkina, E. et al. CXCR6 promotes atherosclerosis by supporting T-cell homing, interferon-gamma production, and macrophage accumulation in the aortic wall. Circulation 116, 1801-1811 (2007).
42. Pryshchep, O., Ma-Krupa, W., Younge, B. R., Goronzy, J. J. & Weyand, C. M. Vessel-specific Toll-like receptor profiles in human medium and large arteries. Circulation 118, 1276-1284 (2008).
43. Gonzalez, A. et al. Mortality trends in rheumatoid arthritis: the role of rheumatoid factor. J. Rheumatol. 35, 1009-1014 (2008).
44. Goodson, N. J. et al. Mortality in early inflammatory polyarthritis: cardiovascular mortality is increased in seropositive patients. Arthritis Rheum. 46, 2010-2019 (2002).
45. Park, Y. B. et al. effects of antirheumatic therapy on serum lipid levels in patients with rheumatoid arthritis: a prospective study. Am. J. Med. 113, 188-193 (2002).
46. Wijbrandts, C. A. et al. Sustained changes in lipid profile and macrophage migration inhibitory factor (MIF) levels after anti-TNF therapy in rheumatoid arthritis. Ann. Rheum. Dis. 68, 1316-1321 (2009).
47. van Eijk, I. C. et al. Improvement of lipid profile is accompanied by atheroprotective alterations in high-density lipoprotein composition upon tumor necrosis factor blockade: a prospective cohort study in ankylosing spondylitis. Arthritis Rheum. 60, 1324-1330 (2009).
48. Hill, J. M. et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N. Engl. J. Med. 348, 593-600 (2003).
49. Grisar, J. et al. Depletion of endothelial progenitor cells in the peripheral blood of patients with rheumatoid arthritis. Circulation 111, 204-211 (2005).
50. Haruna, Y. et al. Fluvastatin reverses endothelial dysfunction and increased vascular oxidative stress in rat adjuvant-induced arthritis. Arthritis Rheum. 56, 1827-1835 (2007).
51. Panoulas, V. F. et al. Long-term exposure to medium-dose glucocorticoid therapy associates with hypertension in patients with rheumatoid arthritis. Rheumatology (Oxford) 47, 72-75 (2008).
52. Rozman, B. et al. Leflunomide and hypertension. Ann. Rheum. Dis. 61, 567-569 (2002).
53. Bresalier, R. S. et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N. Engl. J. Med. 352, 1092-1102 (2005).
54. Lazzerini, P. E. et al. Simvastatin inhibits cytokine production and nuclear factor-κB activation in interleukin 1beta-stimulated synoviocytes from rheumatoid arthritis patients. Clin. Exp. Rheumatol. 25, 696-700 (2007).
55. Yokota, K., Miyazaki, T., Hirano, M., Akiyama, Y. & Mimura, T. simvastatin inhibits production of interleukin 6 (IL-6) and IL-8 and cell proliferation induced by tumor necrosis factor-alpha in fibroblast-like synoviocytes from patients with rheumatoid arthritis. J. Rheumatol. 33, 463-471 (2006).
56. Xu, H. et al. RhoA-mediated, tumor necrosis factor alpha-induced activation of NF-kappaB in rheumatoid synoviocytes: inhibitory effect of simvastatin. Arthritis Rheum. 54, 3441-3451 (2006).
57. Nagashima, T., Okazaki, H., Yudoh, K., Matsuno, H. & Minota, S. Apoptosis of rheumatoid synovial cells by statins through the blocking of protein geranylgeranylation: a potential therapeutic approach to rheumatoid arthritis. Arthritis Rheum. 54, 579-586 (2006).
58. Dombrecht, E. J. et al. Influence of simvastatin on the production of pro-inflammatory cytokines and nitric oxide by activated human chondrocytes. Clin. Exp. Rheumatol. 25, 534-539 (2007).
59. Barsante, M. M. et al. Anti-inflammatory and analgesic effects of atorvastatin in a rat model of adjuvant-induced arthritis. Eur. J. Pharmacol. 516, 282-289 (2005).
60. Palmer, G. et al. Assessment of the efficacy of different statins in murine collagen-induced arthritis. Arthritis Rheum. 50, 4051-4059 (2004).
61. Abud-Mendoza, C. et al. Therapy with statins in patients with refractory rheumatic diseases: a preliminary study. Lupus 12, 607-611 (2003).
62. Kanda, H. et al. Effects of low-dosage simvastatin on rheumatoid arthritis through reduction of Th1/Th2 and CD4/CD8 ratios. Mod. Rheumatol. 17, 364-368 (2007).
63. McCarey, D. W. et al. Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet 363, 2015-2021 (2004).
64. Okamoto, H. et al. Beneficial action of statins in patients with rheumatoid arthritis in a large observational cohort. J. Rheumatol. 34, 964-968 (2007).
65. Maki-Petaja, K. M. et al. Ezetimibe and simvastatin reduce inflammation, disease activity, and aortic stiffness and improve endothelial function in rheumatoid arthritis. J. Am. Coll. Cardiol. 50, 852-858 (2007).
66. Hermann, F. et al. simvastatin improves endothelial function in patients with rheumatoid arthritis. J. Am. Coll. Cardiol. 45, 461-464 (2005).
67. van Leuven, S. I. et al. ApoAI-phosphatidylcholine infusion neutralizes the atherothrombotic effects of C-reactive protein in humans. J. Thromb. Haemost. 7, 347-354 (2009).
68. Bisoendial, R. J. et al. Restoration of endothelial function by increasing high-density lipoprotein in subjects with isolated low high-density lipoprotein. Circulation 107, 2944-2948 (2003).
69. Charles-schoeman, C. et al. Effects of high-dose atorvastatin on antiinflammatory properties of high density lipoprotein in patients with rheumatoid arthritis: a pilot study. J. Rheumatol. 34, 1459-1464 (2007).
70. Reilly, P. A., Cosh, J. A., Maddison, P. J., Rasker, J. J. & Silman, A. J. Mortality and survival in rheumatoid arthritis: a 25 year prospective study of 100 patients. Ann. Rheum. Dis. 49, 363-369 (1990).
71. Jacobsson, L. T. et al. Rheumatoid arthritis and mortality. A longitudinal study in Pima Indians. Arthritis Rheum. 36, 1045-1053 (1993).
72. Pincus, T., Brooks, R. H. & Callahan, L. F. Prediction of long-term mortality in patients with rheumatoid arthritis according to simple questionnaire and joint count measures. Ann. Intern. Med. 120, 26-34 (1994).
73. Myllykangas-Luosujarvi, R., Aho, K., Kautiainen, H. & Isomaki, H. Cardiovascular mortality in women with rheumatoid arthritis. J. Rheumatol. 22, 1065-1067 (1995).
74. Wallberg-Jonsson, S., Ohman, M. L. & Dahlqvist, S. R. Cardiovascular morbidity and mortality in patients with seropositive rheumatoid arthritis in Northern Sweden. J. Rheumatol. 24, 445-451 (1997).
75. Symmons, D. P., Jones, M. A., Scott, D. L. & Prior, P. Longterm mortality outcome in patients with rheumatoid arthritis: early presenters continue to do well. J. Rheumatol. 25, 1072-1077 (1998).
76. Kvalvik, A. G., Jones, M. A. & Symmons, D. P. Mortality in a cohort of Norwegian patients with rheumatoid arthritis followed from 1977 to Scand. J. Rheumatol. 29, 29-37 (1992).
77. Del Rincón, I., Williams, K., stern, M. P., Freeman, G. L. & Escalante, A. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum. 44, 2737-2745 (2001).
78. Bjornadal, L., Baecklund, E., Yin, L., Granath, F., Klareskog, L. & Ekbom, A. Decreasing mortality in patients with rheumatoid arthritis: results from a large population based cohort in Sweden, 1964-1995. J. Rheumatol. 29, 906-912 (2002).
79. Mikuls, T. R. et al. Mortality risk associated with rheumatoid arthritis in a prospective cohort of older women: results from the Iowa women's Health study. Ann. Rheum. Dis. 61, 994-999 (2002).
80. Gabriel, S. E. et al. Survival in rheumatoid arthritis: a population-based analysis of trends over 40 years. Arthritis Rheum. 48, 54-58 (2003).
81. Linos, A., Worthington, J. W., O'Fallon, W. M. & Kurland, L. T. The epidemiology of rheumatoid arthritis in Rochester, Minnesota: a study of incidence, prevalence, and mortality. Am. J. Epidemiol. 111, 87-98 (1980).
82. Allebeck, P., Ahlbom, A. & Allander, E. Increased mortality among persons with rheumatoid arthritis, but where RA does not appear on death certificate. Eleven-year follow-up of an epidemiological study. Scand. J. Rheumatol. 10, 301-306 (1981).
83. Vandenbroucke, J. P., Hazevoet, H. M. & Cats, A. survival and cause of death in rheumatoid arthritis: a 25-year prospective followup. J. Rheumatol. 11, 158-161 (1984).
84. Lindqvist, E. & Eberhardt, K. Mortality in rheumatoid arthritis patients with disease onset in the 1980s. Ann. Rheum. Dis. 58, 11-14 (1999).
85. Sokka, T., Mottonen, T. & Hannonen, P. Mortality in early "sawtooth" treated rheumatoid arthritis patients during the first 8-14 years. Scand. J. Rheumatol. 28, 282-287 (1999).
86. Kroot, E. J. et al. No increased mortality in patients with rheumatoid arthritis: up to 10 years of follow up from disease onset. Ann. Rheum. Dis. 59, 954-958 (2000).
87. Riise, T., Jacobsen, B. K., Gran, J. T., Haga, H. J. & Arnesen, E. Total mortality is increased in rheumatoid arthritis. A 17-year prospective study. Clin. Rheumatol. 20, 123-127 (2001).
88. Peltomaa, R., Paimela, L., Kautiainen, H. & Leirisalo-Repo, M. Mortality in patients with rheumatoid arthritis treated actively from the time of diagnosis. Ann. Rheum. Dis. 61, 889-894 (2002).
89. Grundy, S. M. et al. Implications of recent clinical trials for the National Cholesterol education Program Adult Treatment Panel III guidelines. Circulation 110, 227-239 (2004).